Prospective validation of a prognostic score for patients in immunotherapy phase I trials: The Gustave Roussy Immune Score (GRIm-Score)-Reference-Cited by-同舟云学术

Prospective validation of a prognostic score for patients in immunotherapy phase I trials: The Gustave Roussy Immune Score (GRIm-Score)

Published:2017-10 Issue: Volume:84 Page:212-218
ISSN:0959-8049
Container-title:European Journal of Cancer
language:en
Short-container-title:European Journal of Cancer

Author:

Bigot Frédéric,Castanon Eduardo,Baldini Capucine,Hollebecque Antoine,Carmona Alberto,Postel-Vinay Sophie,Angevin Eric,Armand Jean-Pierre,Ribrag Vincent,Aspeslagh Sandrine,Varga Andrea,Bahleda Rastislav,Menis Jessica,Gazzah Anas,Michot Jean-Marie,Marabelle Aurélien,Soria Jean-Charles,Massard Christophe

Publisher

Elsevier BV

Subject

Cancer Research,Oncology

Reference40 articles.

1. Multivariable analysis of prognostic factors for toxicity and survival for patients enrolled in phase I clinical trials;Bachelot;Ann Oncol,2000

2. Dose-response relationship in phase i clinical trials: a European Drug Development Network (EDDN) Collaboration Study;Moreno García;Clin Cancer Res,2014

3. Clinical outcome and prognostic factors for patients treated within the context of a phase I study: the Royal Marsden Hospital experience;Arkenau;Br J Cancer,2008

4. 90-days mortality rate in patients treated within the context of a phase-I trial: how should we identify patients who should not go on trial?;Arkenau;Eur J Cancer (Oxford England: 1990),2008

5. Development and validation of a model that predicts early death among cancer patients participating in phase I clinical trials investigating cytotoxics;Penel;Invest New Drugs,2010

Cited by 150 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy, safety, and prognostic modeling in neoadjuvant immunotherapy for esophageal squamous cell carcinoma;International Immunopharmacology;2024-12

2. Conversion Surgery After Chemotherapy Plus Nivolumab as the First-Line Treatment for Unresectable Advanced or Recurrent Gastric Cancer and a Biomarker Study Using the Gustave Roussy Immune Score: A Multicenter Study;Annals of Surgical Oncology;2024-09-03

3. Impact of histologically poorly cohesive phenotype as a prognostic factor in patients with pStage II/III gastric cancer undergoing adjuvant chemotherapy;2024-08-18

4. The Gustave Roussy Immune score is a powerful biomarker for predicting therapeutic resistance to chemotherapy in gastric cancer patients;Cancer Chemotherapy and Pharmacology;2024-07-25

5. How General and Inflammatory Status Impacts on the Prognosis of Patients Affected by Lung Cancer: State of the Art;Biomedicines;2024-07-12